课题基金 / 基金详情

CLINICAL TRIAL: ACTG A5229 TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY

CLINICAL TRIAL: ACTG A5229 TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY
临床试验:ACTG A5229 补充尿苷治疗 HIV 脂肪萎缩的试验
批准号:
7950961
负责人:
DANIEL LEE
金额:
$0.83万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

DANIEL LEE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Examine the effect of uridine supplementation on limb fat in HIV-1 infected subjects with clinical lipoatrophy by comparing changes from baseline to week 48 in DEXA measured limb fat between the urdine arm and the placebo arm.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: ACTG A5229 TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY
FRAM 2 FAT REDISTRIBUTION & METABOLIC CHANGE IN HIV INFECTION
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data